A novel platform to enable inhaled naked rnai medicine for lung cancer

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Fujita, Yu ^a,b   Takeshita, Fumitaka ^a   Mizutani, Takayuki ^c   Ohgi, Tadaaki ^c   Kuwano, Kazuyoshi ^b   Ochiya, Takahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c BONAC Corporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; DRUG CARRIER; GLYCOSYLTRANSFERASE; LUCIFERASE; NOSE SPRAY; PROTEASOME; RPN2 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ADENOCARCINOMA; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; GENETICS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG; LUNG NEOPLASMS; MALE; MOUSE; PATHOLOGY; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ADENOCARCINOMA; ADMINISTRATION, INHALATION; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; DRUG CARRIERS; HEXOSYLTRANSFERASES; HUMANS; LUCIFERASES; LUNG; LUNG NEOPLASMS; MALE; MICE; MICE, SCID; NASAL SPRAYS; NEOPLASM TRANSPLANTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84888610334     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03325     Document Type: Article

References (26)

1. Matranga, C., Tomari, Y., Shin, C., Bartel, D. P. & Zamore, P. D. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123, 607-620 (2005). (Pubitemid 41608464)
2. Davidson, B. L.McCray, P. B., Jr. Current prospects for RNAinterference-based therapies. Nat Rev Genet 12, 329-340 (2011).
3. Takeshita, F. & Ochiya, T. Therapeutic potential of RNA interference against cancer. Cancer Sci 97, 689-696 (2006). (Pubitemid 43983779)
4. Kim, D. H. & Rossi, J. J. Strategies for silencing human disease using RNA interference. Nat Rev Genet 8, 173-184 (2007).
5. Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G. & Sood, A. K. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11, 59-67 (2011).
6. Chernolovskaya, E. L. & Zenkova, M. A. Chemical modification of siRNA. Curr Opin Mol Ther 12, 158-167 (2010).
7. Lares, M. R., Rossi, J. J. & Ouellet, D. L. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 28, 570-579 (2010).
8. Zhou, J., Bobbin, M. L., Burnett, J. C. & Rossi, J. J. Current progress of RNA aptamer-based therapeutics. Front Genet 3, 234 (2012).
9. Hamasaki, T. et al. Efficacy of a novel class of RNA interference therapeutic agents. PLoS One 7, e42655 (2012).
10. Molina, J. R., Yang, P.,Cassivi, S. D., Schild, S. E.Adjei, A. A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83, 584-594 (2008). (Pubitemid 351720831)
11. Ramalingam, S. S., Owonikoko, T. K. & Khuri, F. R. Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin 61, 91-112 (2011).
12. Herbst, R. S., Heymach, J. V. & Lippman, S. M. Lung cancer. N Engl J Med 359, 1367-1380 (2008).
13. Pao, W. & Girard, N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 12, 175-180 (2011).
14. Agu, R. U., Ugwoke, M. I., Armand, M., Kinget, R. & Verbeke, N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2, 198-209 (2001). (Pubitemid 34187927)
15. Lam, J. K., Liang, W.Chan,H. K. Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev 64, 1-15 (2012).
16. Morin, A., Gallou-Kabani, C., Mathieu, J. R. & Cabon, F. Systemic delivery and quantification of unformulated interfering RNAs in vivo. Curr Top Med Chem 9, 1117-1129 (2009).
17. Heidel, J. D., Hu, S., Liu, X. F., Triche, T. J. & Davis, M. E. Lack of interferon response in animals to naked siRNAs. Nat Biotechnol 22, 1579-1582 (2004). (Pubitemid 40039462)
18. Burnett, J. C. & Rossi, J. J. RNA-based therapeutics: current progress and future prospects. Chem Biol 19, 60-71 (2012).
19. Schlee, M., Hornung, V. & Hartmann, G. siRNA and isRNA: two edges of one sword. Mol Ther 14, 463-470 (2006). (Pubitemid 44296098)
20. Petrocca, F. & Lieberman, J. Promise and challenge of RNA interference-based therapy for cancer. J Clin Oncol 29, 747-754 (2011).
21. Honma, K. et al. RPN2 gene confers docetaxel resistance in breast cancer. NatMed 14, 939-948 (2008).
22. Zhu, J., He, J., Liu, Y., Simeone, D. M. & Lubman, D. M. Identification of glycoprotein markers for pancreatic cancer CD241CD441 stem-like cells using nano-LC-MS/MS and tissue microarray. J Proteome Res 11, 2272-2281 (2012).
23. Kurashige, J. et al. RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma. Br J Cancer 107, 1233-1238 (2012).
24. Takahashi, R. et al. Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3b. Sci. Rep. 3, 2474; doi:10.1038/srep02474 (2013).
25. Han, J. & Burgess, K. Fluorescent indicators for intracellular pH. Chem Rev 110, 2709-2728 (2010).
26. Bivas-Benita, M., Zwier, R., Junginger, H. E. & Borchard, G. Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm 61, 214-218 (2005). (Pubitemid 41427629)